Valuation: Univo Pharmaceuticals Ltd

Market Cap 56.8M 0 50.88M 46.94M 42.48M 79.43M 5.41B 80.71M 560M 223M 2.83B 213M 209M 8.97B P/E 2019 *
-
P/E 2020 -
Enterprise Value 60.92M 0 54.57M 50.34M 45.56M 85.19M 5.8B 86.57M 601M 240M 3.04B 229M 224M 9.62B EV / Sales 2019
35,543,010x
EV / Sales 2020 2,352,105x
Free-Float
63.83%
Yield 2019 *
-
Yield 2020 -
Current month+900.00%
Current year+900.00%
5 years 90,000
Extreme 90000
2,745,000
10 years 90,000
Extreme 90000
7,488,000
Manager TitleAgeSince
Chief Executive Officer 50 2018-09-05
Investor Relations Contact - -
Comptroller/Controller/Auditor 44 2021-12-31
Director TitleAgeSince
Chairman 66 2019-07-14
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 918K
+0.34%-3.03%+37.45%+61.06% 64.14B
+0.98%+2.68%+12.25%+83.90% 55.53B
+1.75%+2.01%+13.30%+105.71% 53.03B
-2.18%-1.64%+25.67%+54.52% 45.99B
-1.06%-3.38%+17.31%+97.93% 42.45B
+0.13%+0.23%+224.25%+925.23% 40.45B
-0.26%-4.20%+10.86%+45.18% 32.25B
-2.07%+42.73%+103.77%+90.26% 34.47B
-2.72%-8.79%+22.58%-5.63% 24.23B
Average -0.55%+3.44%+51.94%+162.02% 39.25B
Weighted average by Cap. -0.35%+3.13%+49.03%+159.74%

Financials

2019 2020
Net sales 0.82 0 0.74 0.68 0.62 1.15 78.47 1.17 8.12 3.24 41.07 3.09 3.03 130.07 33.68 0 30.17 27.83 25.19 47.09 3.21K 47.86 332.04 132.46 1.68K 126.4 123.71 5.32K
Net income -11.79M -0 -10.56M -9.74M -8.82M -16.48M -1.12B -16.75M -116M -46.37M -588M -44.24M -43.3M -1.86B 183K 0 164K 151K 137K 256K 17.43M 260K 1.8M 720K 9.12M 687K 672K 28.89M
Net Debt -22.82M -0 -20.44M -18.86M -17.06M -31.91M -2.17B -32.42M -225M -89.75M -1.14B -85.64M -83.82M -3.6B 4.12M 0 3.69M 3.4M 3.08M 5.76M 392M 5.85M 40.62M 16.2M 205M 15.46M 15.13M 650M
Logo Univo Pharmaceuticals Ltd
Univo Pharmaceuticals Ltd is an Israel-based biotech company. The Company is focused on developing drugs for the treatment of central nervous system (CNS) conditions. Its area of interest is in developing medicine for degenerative and age-related disorders. The Company’s product portfolio includes three clinical Phase II drug-candidates: THR-18 for thrombolysis, to restore blood flow to the brain, heart or lungs, which completed clinical Phase I and Phase II study in acute stroke patients receiving tPA; DP-VPA for the treatment of epilepsy, migraine and manic depression, which has completed a Phase II study in patients with complex partial epilepsy, and DP-b99, which contains calcium, zinc and copper ions and is used for the protection of cells under stress in acute pancreatitis. The Firm’s two technology platforms Membrane Activated Chelator and Regulated Activation of Prodrug use lipid moieties conjugated onto actives such as metal ion chelators or drugs for site specific activation.
Employees
-
Date Price Change
26-10-29 ILA 930,000.00 0.00%
26-10-28 ILA 930,000.00 0.00%
26-10-26 ILA 930,000.00 0.00%
26-10-23 ILA 930,000.00 0.00%
26-10-22 ILA 930,000.00 0.00%
  1. Stock Market
  2. Stocks
  3. UNVO-M Stock